Updated:
Sangel Capital
Sangel Capital is a venture capital and business finance firm based in Shenzhen, China. It invests in high-tech enterprises in China and Western countries,...
Sangel Capital
Sangel Capital is a venture capital and business finance firm based in Shenzhen, China. It invests in high-tech enterprises in China and Western countries, focusing on sectors such as biomedicine, medical devices, healthcare, and biotech. The firm has made 57 investments, including a Series A investment in Proviva Therapeutics on March 05, 2024, and has facilitated 4 portfolio exits, including the sale of Ultivue on October 09, 2024.
General information
Firm type
Private Equity
Location
Region
Asia
Country
China
City
Shenzhen
Corporate office
Shenzhen, China
Frequently asked questions
What investment stages does Sangel Capital typically target?
Sangel Capital describes its strategy as covering early-stage, seed, start-up, and growth-stage venture investments. The firm has not published specific check sizes, ownership targets, or stage allocation breakdowns, so precise preferences across these stages cannot be confirmed from public sources.
Which sectors does Sangel Capital focus on?
Sangel Capital has not published a sector-specific investment thesis or any named portfolio companies. Based on its Shenzhen location and the city's concentration of hardware, electronics, and deep-tech startups, exposure to these sectors is plausible but unconfirmed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: